Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK and Sepracor announce Lunivia commercialisation agreement

GSK and Sepracor announce Lunivia commercialisation agreement

12th September 2007

GlaxoSmithKline (GSK) and Sepracor have this week signed an international alliance agreement for the commercialisation of Lunivia (eszopiclone) worldwide – with the exception of the US, Canada, Japan and Mexico.

Under the terms of the agreement, GSK will pay Sepracor an initial sum of $20 million (9.86 million pounds) with further milestone payments upon the attainment of specified landmarks up to $155 million, in addition to double-digit royalties that will rise with product sales.

The compound is currently being reviewed by the centralised procedure of the European Medicines Agency as a treatment for insomnia, with potential approval in up to 27 member states of the EU dependent on national reimbursement approvals and pricing.

Andrew Witty, president of pharmaceuticals in Europe for GSK, said: “When untreated, insomnia can have serious health and social consequences.

“Upon approval, Lunivia will be an additional option for people suffering from insomnia – it has a proven benefit in chronic insomnia in helping sufferers get to sleep and stay asleep.”

He added that the company is pleased to partner Sepracor to provide this new treatment option for both insomnia patients in Europe and those across the globe.

In November 2005, research by UK scientists revealed that the benefits of using sedatives in older patients may be outweighed by the risk.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.